- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.53 Å
- Oligo State
- monomer
- Ligands
- 1 x YDA: 1-~{tert}-butyl-~{N}-[(5~{R})-8-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-2-(oxetan-3-yl)-1,3,4,5-tetrahydro-2-benzazepin-5-yl]-1,2,3-triazole-4-carboxamide(Non-covalent)
- 1 x DTT: 2,3-DIHYDROXY-1,4-DITHIOBUTANE(Non-covalent)
- 2 x ACT: ACETATE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Hopkins, B.T. et al., Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. J.Med.Chem. (2022)
- Release Date
- 2022-01-12
- Peptides
- Isoform BTK-C of Tyrosine-protein kinase BTK: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A